凝血因子XII有助于蛋白激活,心力衰竭的进展和死亡率
bioRxiv : the preprint server for biology
|September 24, 2024
概括
激活的凝血因子XII产生活跃的氨酸,通过过度激活氨酸- ангиотензин- 阿尔多素系统 (RAAS),导致心力衰竭和死亡率. 这一发现为心力衰竭治疗提供了新的治疗点.
科学领域:
- 心血管医学 心血管医学
- 血液静止和血栓形成
- 脏生理学 脏生理学
背景情况:
- 症状性心力衰竭 (sHF) 涉及心脏功能障碍,胀和死亡率,通常是由氨酸-氨酸-阿尔多斯特系统 (RAAS) 的过度活化驱动的.
- 列宁启动RAAS级联,但其在病理条件下激活的精确机制在很大程度上是未知的.
研究的目的:
- 阐明在症状性心力衰竭的背景下负责蛋白激活的上游机制.
- 确定在sHF和相关疾病中调节RAAS的新型治疗点.
主要方法:
- 使用相关的生物测定和模型研究了凝血因子XII在蛋白激活中的作用.
- 在实验环境中评估了激活XII因子,蛋白活性,RAAS标志物和心力衰竭进展之间的联系.
主要成果:
- 证明激活的凝血因子XII直接在循环中产生活跃的氨酸.
- 在激活的XII因子,病态RAAS激活和sHF的发展之间建立了直接的相关性.
- 在sHF模型中展示了这种途径与死亡率增加的关联.
结论:
- 激活凝血因子XII是renin的关键上游激活剂,将血静与sHF中的RAAS过度激活联系起来.
- 这一发现为管理RAAS驱动的症状性心力衰竭提供了一个新的治疗策略.
- 针对 XII 凝血因子和雷宁之间的相互作用,可能为治疗 sHF 和其他相关病理提供一个新的范式.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:25Antihypertensive Drugs: Direct Renin Inhibitors
508
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
01:33Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
492
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
492